Sartorius Stedim Biotech S.A.

SDMHF | OTC

Price Alert Chart Builder DCF Calculator

$248.00

-$6.56 (-2.58%)

At close: Oct 30, 2026, 10:10 AM ET

$248.00

$0.00 (0.00%)

After-hours: Oct 30, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

-2.58%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

44.3

+10.8 pts

Fundamentals Average

Market Sentiment Bullish

Moat Narrow

Sector Rank #413/1028 (Top 40%)

Full Analysis

Key Statistics

Market Data

Market Cap $24.13B

1D Range

248.00 251.00

52W Range

178.30 259.65

Valuation (TTM)

PE 63.91

PB 4.86

EV/EBITDA 26.02

Valuation (NTM)

Forward PE 37.72

Forward PEG 5.08

Price Target N/A

Cash Flow

FCF Yield 1.3%

SBC Adj. FCF Yield 1.3%

SBC Impact N/A

Margins

Gross Margin 44.5%

Operating Margin 19.4%

FCF Margin 8.8%

Growth (CAGR)

Revenue 3Y | 5Y 1.1% | 3.0%

Dil EPS 3Y | 5Y -12.3% | -10.5%

FCF 3Y | 5Y 31.9% | -5.5%

Returns

ROA 4.0%

ROE 7.7%

ROIC 6.0%

Financial Health

Net Debt

€1.99B ($2.26B)

Current Ratio 1.22

Interest Coverage 3.78

Dividends

Div Yield 0.32%

Payout Ratio 24.0%

FCF Payout Ratio 24.9%

All Key Statistics

Loading financial charts...

Profile

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; c...

Sector Healthcare

Industry Medical - Instruments & Supplies

Employees 10,265

IPO Date Aug 3, 2009

Website www.sartorius.com

Fiscal Year January - December

Full Company Profile

Latest News

2 months ago · seekingalpha.com

Baron International Growth Fund Q2 2026 Portfolio Activity

Baron International Growth Fund gained 14.05% (Institutional Shares) during the second quarter of 2026, while its primary benchmark, the MSCI ACWI ex USA Index, returned 14.49%. During the second quarter, we added a few new investments to existing themes and increased our weighting in certain positions established in prior periods. We exited a few positions during the quarter consistent with our efforts to seek greater concentration in our higher conviction investments.

Earnings

Latest Earnings

Oct 22, 2026

EPS

$1.34

Miss -2.19%

YoY: +21.82%

REV

$863.34M

Beat +0.70%

YoY: +4.26%

Next Earnings

Feb 23, 2027

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞